
Opinion|Videos|March 15, 2024
Clinical Pearls for the Treatment of Patients with Myelofibrosis
Author(s)John Mascarenhas, MD
In closing the discussion, Dr Mascarenhas shares clinical pearls for community oncologists treating patients with myelofibrosis.
Advertisement
Episodes in this series

Case: A 62-Year-Old Man with Myelofibrosis
Clinical Presentation:
- A 62-year-old man presented with symptoms of fatigue, night sweats, and increased bruising.
- PMH: type 2 diabetes, hypercholesteremia, and hypertension
- 1 year prior, patient had a “normal” physical and blood work.
- PCP noticed lower Hg (11 to 9.5 g/dL) and Plt (350 to 195 cells/m3)
- Patient was referred to Hem/Onc – first available appoint in 2 months.
Initial Clinical Workup and Diagnosis (Post-PCP Visit):
- Exam: fatigue and night sweats worsening; bone pain.
- Labs: RBC 3.40 x 1012/L; Hb 8.7 g/dL; Hct 36%; MCV 94fL; WBC 28.0 x 109/L; Plt 75 x 109/; LDH 330 IU/L
- Spleen: 5 cm below LCM
- Bone Marrow Fibrosis: Grade 2
- Bone Marrow Blasts: 3%
- Blood Smear: leukoerythroblastosis; 1% blasts by manual count/flow cytometry
- Molecular Analysis: JAK V617F+
- ECOG PS 2
- Diagnosis: Primary MF
Current Treatments:
- Patient was initiated on pacritinib.
Advertisement
Related to this article

Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5

